Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

Mooi instap moment Dendreon

1.743 Posts
Pagina: «« 1 ... 22 23 24 25 26 ... 88 »» | Laatste | Omlaag ↓
  7. [verwijderd] 28 februari 2007 16:51

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    snor13854 schreef:

    Bedankt Crackedtooth,al vast wat,tradebox ligt erwel meer uit op dagen zo als deze?
    RB
    ik gebruik interactive brokers (erg goedkoop aan/verkoop en goed systeem voor nasdaq)
    dat is het systeem dat todaysbrokers als tussenpersoon gebruikt,en waar ze stuk duurder zijn dan IB zelf

    wil tzt nog bij ABN openen om bv australie etc te kunnen kopen
  9. [verwijderd] 28 februari 2007 17:50

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    snor13854 schreef:

    Hij is er weer,maar mis wel mijn aankoopplan om op 4.50 bij te kopen.
    Jammer.
    Ik ga dat eens proberen met IB.
    rb

    check website maar
    voor daytraden (zijn sec regels voor) moet je wel minimaal 25k us$ balans hebben

    maar voor US en vooral nasdaq erg fijn
    level2 kost 20/30$ per maand, dat is gewoon was nasdaq zelf berkent
    zit een ruwe realtime chart bij als je wilt met oa fibonacci

    en je kan per muisklik traden vanuit level 2 boekje
    shorten doe ik niet, maar je kan ook oa insm shorten (goedkope aandleen dus ook)

    voor/nabeurshandelen

    is wel .uk bedrijf, dus als je je daar ongemakkelijk over voelt dan moet je todaysbroker gaan, zelfde systeem, nederlandse shell ervan
    alleen iets duurder

    check IB website voor kosten
    nasdaq=0,05 cent per aandeel
  13. [verwijderd] 1 maart 2007 12:09

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Het spel is op de wagen!!

    PB

    Dendreon Announces FDA's Cellular, Tissue and Gene Therapies Advisory Committee to Review Provenge(R) for the Treatment of Asymptomatic, Metastatic, Androgen-Independent Prostate Cancer

    SEATTLE, WA, March 1, 2007 - Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration's Office of Cellular, Tissue and Gene Therapies Advisory Committee will review the Biologics License Application (BLA) for PROVENGE (sipuleucel-T), the Company's investigational active cellular immunotherapy (ACI) for the treatment of asymptomatic, metastatic, androgen-independent (also known as hormone refractory) prostate cancer on March 29, 2007. The Center for Biologics Evaluation and Research (CBER) has oversight of the Cellular, Tissue and Gene Therapy Advisory Committee.

    Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 218,890 new cases of prostate cancer diagnosed each year. More than 27,000 men die each year of the disease.

    The BLA submission is based primarily on an improvement in overall survival observed in Study D9901, a multi-center, randomized, double-blind, placebo-controlled Phase 3 Study. The results from D9901 were published in the July issue of the Journal of Clinical Oncology.

    Dendreon completed the submission of its BLA for PROVENGE in November 2006, and the FDA accepted the filing and assigned Priority Review status for the application in January 2007. Priority Review is granted to products that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious or life-threatening disease. Based on the FDA's designation of Priority Review for PROVENGE, the Company anticipates action by the FDA approximately six months from the submission date, or by May 15, 2007.

    About PROVENGE

    PROVENGE is an investigational product that may represent the first in a new class of active cellular immunotherapies that are uniquely designed to stimulate a patient's own immune system. PROVENGE is in late-stage clinical development for the treatment of patients with advanced prostate cancer. In clinical studies, patients typically received three infusions over a one-month period as a complete course of therapy.

    P.
  17. [verwijderd] 1 maart 2007 14:22

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    From Briefing.com
    08:11 CALLS Research Notable Mentions I

    JMP Securities notes that last night, the FDA scheduled Dendreon's (DNDN 4.64) Provenge BLA to go in front of the Center for Biologics Evaluation and Research committee, a division of the FDA, on March 29, 2007. Based on CBER's familiarity and positive review of the Provenge clinical package, including granting Fast Track status, rolling BLA submission, accepting the survival benefit endpoint, and adjusting the SPA on the ongoing Phase III (IMPACT, a.k.a. D9902B), they favorably view a panel meeting with the Cellular, Tissue, and Gene Therapies Advisory Committee, a division of CBER, potentially lowering the regulatory risk of the filing, which could exist if ODAC were the reviewing entity. While they expect the FDA to issue an approvable letter pending interim data from the ongoing IMPACT trial (n=500), they believe this notion is already priced into the stock... Jefferies notes that ICF International's (ICFI 14.77) large and controversial Road Home contract has posted a material acceleration in case closings recently. With headline risk easing here, combined with what the firm feels could be a strong Q4, they see very good risk reward in ICFI ahead of their Q4 earnings release. Wachovia comments on Gilead (GILD 71.56), saying future GS-9137 revenues are not accounted for in their valuation of GILD at this time given expected market launch in 2H '09 at the earliest. With a probable approval of ambrisentan in June already reflected in GILD's share price, they do not expect any catalysts to drive the stock to meaningful new highs for the remainder of the year. They think growth of the existing HIV franchise is also reflected in GILD's share price as well... Jefferies raises their Assisted Living Concepts (ALC 11.43) tgt to $13.25 from $9.25 following solid 4Q06 results. They continue to believe ALC's portfolio provides significant potential for organic revenue and EBITDAR growth


1.743 Posts
Pagina: «« 1 ... 22 23 24 25 26 ... 88 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.017
AB InBev 2 5.496
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.651
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.645
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.751
Aedifica 3 916
Aegon 3.258 322.835
AFC Ajax 538 7.088
Affimed NV 2 6.296
ageas 5.844 109.892
Agfa-Gevaert 14 2.050
Ahold 3.538 74.336
Air France - KLM 1.025 35.043
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.824
Allfunds Group 4 1.473
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.181
AMG 971 133.338
AMS 3 73
Amsterdam Commodities 305 6.689
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 14.998
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.776
Arcelor Mittal 2.033 320.709
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.300
Aroundtown SA 1 219
Arrowhead Research 5 9.739
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.097
ASML 1.766 107.195
ASR Nederland 21 4.486
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.667
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392